Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ortho-hydroxybenzoic acid or derivative doai
Reexamination Certificate
2002-04-05
2010-12-14
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ortho-hydroxybenzoic acid or derivative doai
C514S167000
Reexamination Certificate
active
07851461
ABSTRACT:
The present invention relates to a method for prevention of epithelial cancer such as lung, bladder, prostate or gynaecological cancer or the initiation and/or progression of epithelial cancer such as lung, bladder, prostate or gynaecological cancer in a human comprising administering to the human of a combination dosage of a cyclooxygenase (COX) inhibitor, a vitamin D3including analogues and metabolites thereof and/or calcium. In a further aspect the invention relates to a method for reducing the effective dosage of ASA in a chemopreventive treatment of epithelial cancer in a human by co-administration with a non toxic dosage of a vitamin D3including analogues and metabolites thereof and/or Ca in the form of a combination dosage. In another embodiment the invention relates to the use of a cyclooxygenase (COX) inhibitor, a vitamin D3including analogues and metabolites thereof and/or calcium for the preparation of a medicament for the prevention of epithelial cancer such as lung, bladder, prostate or gynaecological cancer or the initiation and/or progression of epithelial cancer such as lung, bladder, prostate or gynaecological cancer.
REFERENCES:
patent: 5770215 (1998-06-01), Moshyedi
patent: 5948443 (1999-09-01), Riley et al.
patent: 43 34 154 (1995-04-01), None
patent: 0 205 025 (1986-12-01), None
patent: 0 412 110 (1993-07-01), None
patent: WO 96/41645 (1996-12-01), None
patent: WO 89/10351 (1989-11-01), None
patent: WO 93/09093 (1993-05-01), None
patent: WO 93/19044 (1993-09-01), None
patent: WO 94/14766 (1994-07-01), None
patent: WO 94/26707 (1994-11-01), None
patent: WO 95/02577 (1995-01-01), None
patent: WO 95/03273 (1995-02-01), None
patent: 01/22974 (2001-04-01), None
Steele et al., Journal of Cellular Biochemistry, Supplement 20:32-54 (1994).
Feskanich et al. British Journal of Cancer, 2007, vol. 97, pp. 1295-1299.
Michaud et al. Am. J. Epidemiol., 2000, vol. 152, No. 12, pp. 1145-1153.
Trujillo, M. A. et al., Dig. Dis. Sci. 39:2260-2266 (1994), “Non-steroidal antiinlfammatory agents in chemoprevention of colorectal cancer. At what cost?”.
Caplan, L. S. et al., Curr. Opin. Oncol 8:441-446 (1996), “Secondary prevention of cancer”.
Key, Jak et al., BMJ 313:775-779 (1996), “Dietary habits and mortality in 11000 vegetarians and health conscious people: results of a 17 year follow-up”.
Garland, C. F. et al., Lancet 307-309 (1985), “Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men”.
Garland, C. F. et al., Lancet 18:1176-1178 (1989), “Serum 25 hydroxyvitamin D and colon cancer: eight-year prospective study”.
Garland, C. F. et al., Am. J. Clin. Nutr. 54:193S-201S (1991), “Can colon cancer incidence and death rates be reduced with calcium and vitamin D?”.
Kune, G. A. et al., “Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study”, (1988) Cancer Res. 48:4399-4404.
Suh, O. et al., Cancer 72:1171-1177 (1993), “Aspirin use, cancer and polyps of the large bowel”.
Thun, M. J. et al., “Aspirin use and reduced risk of fatal colon cancer”, 1991 N. Engl. J. Med. 325:1593-1596.
Buring, J. E. et al., “Nonsteroidal antiinflammatory drugs and colorectal cancer”, 1994 Cancer 74:1837-1839.
Heath, C. W. et al., “Nonsteroidal antiinflammatory and human cancer”, 1994 Cancer 74:2885-2888.
Pence, BC., “Role of calcium in colon cancer prevention: experimental and clinical studies”, 1993 Mut Res 290:87-95.
Duris, I. et al., “Calcium chemoprevention in colorectal cancer”, 1996 Hepatogastro-enterol 43:152-154.
Buset, M. et al., “Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium” 1986 Cancer Res. 46:5426-5430.
Wargovich, M. J. et al., “Calcium and vitamin D modulate mouse colon epithelial proliferation and growth characteristics of a human colon tumor cell line”, 1987 Can J. Physiol Pharmacol 65:472-477.
Dorudi, S. et al., “Levels of expression of E-cadherin m-RNA in colorectal cancer correlates with clinical outcome”, 1995 Br. J. Cancer 71:614-616.
Newmark, H. L. et al., “Calcium, vitamin D and colon cancer”, 1992 Cancer Research 52:20067S-2070S.
Rasmussen, H., “The calcium messenger system”, 1986 N. Engl. J. Med 314:1094-1101.
Llor, X et al., “K-ras mutations in 1,2 dimethylhydrazine induced colonic tumors: effects of supplemental diatary calcium and vitamin D deficiency”, 1991 Cancer Res. 51. 4305-4309.
Reshef, R. et al., “Effect of a calcium enriched diet on the colonic epithelial hyperproliferation induced by N-methyl-N-nitro-N-nitrosoguanidine in rats on a low calcium and fat diet”, 1990 Cancer Res. 50:1764-1767.
Kane, K. F. et al., “Functional vitamin D3 receptors are present in human colorectal neoplasms”, 1995 Gastroente-rology 108:A487.
Cross, H. S. et al., “Vitamin D receptor and cytokeratin expression may be expression indicators in human colon cancer”, 1996 Anticancer Res. 16: 2333-2338.
Eisman, J. A. et al., “Suppression of in vivo growth of human cancer solid xenografts by 1,25-dihydroxyvitamin D3”, 1987 Cancer Res. 47:21-25.
Ternent, C. et al., “Lipoxygenase blockade inhibits growth factor-induced colonic cancer cell proliferation”, 1999 Abstract, ASCRS Ann. Meeting 1999.
Marcus, A. J., “Aspirin as prophylaxis against colorectal cancer”, 1995 N. Engl. J. Med. 333:656-658.
Frolich, J. C., “A classification of NSAIDs according to the relative inhibition of cyclooxygenase enzymes”, 1997 TIPS 18: 30-34.
Hanif, A. P. et al., “NSAIDs inhibit the growth of colon cancer cell lines by a prostaflandin independant pathway”, 1995 Gastroente-rology 108:A478.
Ahnen, D. et al., “Sulindac sulfide and sulfone both inhibit the growth of colon cancer cell lines by inducing apoptosis”, 1995 Gastroente-rology 108:A443.
Alberts, D. S. et al., “Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?”, 1995 J. Cell Biochem s22: 18-23.
Kahlenberg, M. et al., “Nonsteroidal antiinflammatory drugs (NSAID's) reduce genomic instability in colorectal tumor cells”, 1998 Abstract. Surgical Oncology Societies 51stAnnual Cancer Symposium 1998.
Levy, G., “Prostataglandin H synthases, nonsteroidal antiinflammatory drugs and colon cancer”, 1997 FASEB J.11:234-247.
Hixson, L. J. et al., “Antiproliferative effect of non-steroidal antiinfiammatory drugs against human colon cancer cells”, 1994 Cancer Epidemiol Biomarkers Prev. 3:5:433-438.
Dubois. R. N. et al, “Nonsteroidal antiinfiammatory drugs, eicosanoids and colorectal cancer prevention”, 1996 Gastroenterol Clin. N. Am. 25:773-791.
Watson, A J., “Chemopreventive effects of NSAIDs against colorectal cancer:regulation of apoptosis and mitosis by C0X-1 and COX-2”, 1998 Histol Histopathol 13:591-597.
Steering Committee of the Physicians Health Study Research Group, “Final report on the aspirin component of the ongoing Physician Health Study”, 1989 N. Engl. J. Med. 321:129-135.
Muscat, J. E. et al., “Nonsteroidal Antiinflammatory drugs and colorectal cancer”, 1994 Cancer 74:1847-1854.
Giovannucci, E. et al., “Aspirin and the risk of colorectal cancer in women”, 1995 N. Engl. J. Med. 333:609-614.
Giovannucci, E. et al., “Aspirin use and the risk of colorectal cancer and adenoma in male health professionals”, 1994 Ann. Int. Med. 121:241-246.
Pollard, M. et al., “Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine”, 1981 Science 214:558-559.
Reddy, B. S. et al., “Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti
Anderson James D
Colotech A/S
Knobbe Martens Olson & Bear LLP
LandOfFree
Combination dosage of a cyclooxygenase (COX) inhibitor, a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination dosage of a cyclooxygenase (COX) inhibitor, a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination dosage of a cyclooxygenase (COX) inhibitor, a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186597